EGFR and non-small cell lung carcinoma: Based on the comprehensive evidence collected, the use of third-generation EGFR-TKI combined with WBRT is recommended as the preferred treatment for NSCLC patients with brain metastases, offering superior management of metastatic brain lesions.<h4>Systematic review registration</h4>https://www.crd.york.ac.uk/PROSPERO/#, CRD42023415566.